Cardiol Historical Income Statement
| CRDL Stock | CAD 2.26 0.05 2.16% |
Historical analysis of Cardiol Therapeutics income statement accounts such as Interest Income of 2.9 M, Depreciation And Amortization of 190.7 K or Interest Expense of 23.4 M can show how well Cardiol Therapeutics Class performed in making a profits. Evaluating Cardiol Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cardiol Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cardiol Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cardiol Therapeutics is a good buy for the upcoming year.
Cardiol |
About Cardiol Income Statement Analysis
Cardiol Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cardiol Therapeutics shareholders. The income statement also shows Cardiol investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cardiol Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cardiol Therapeutics. It is also known as Cardiol Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Cardiol Therapeutics income statement and represents the costs associated with goods and services Cardiol Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Cardiol Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Cardiol Therapeutics' Net Interest Income is very stable compared to the past year. As of the 29th of November 2024, Interest Income is likely to grow to about 2.9 M, while Depreciation And Amortization is likely to drop about 190.7 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 220.4K | 219.9K | 248.4K | 190.7K | Interest Income | 6.9M | 1.2M | 2.2M | 2.9M |
Cardiol Therapeutics income statement Correlations
Click cells to compare fundamentals
Cardiol Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiol Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 244.8K | 76.6K | 106.0K | 1.2M | 2.2M | 2.3M | |
| Interest Income | 145.6K | 42.1K | 6.9M | 1.2M | 2.2M | 2.9M | |
| Depreciation And Amortization | 150.6K | 229.5K | 220.4K | 219.9K | 248.4K | 190.7K | |
| Interest Expense | 621.0 | 0.0 | 106.0K | 19.4M | 22.3M | 23.4M | |
| Selling General Administrative | 10.4M | 9.9M | 27.9M | 22.4M | 15.6M | 14.6M | |
| Gross Profit | (150.6K) | (229.5K) | 78.8K | (219.9K) | (248.4K) | (235.9K) | |
| Other Operating Expenses | 14.1M | 20.7M | 38.7M | 41.3M | 29.8M | 24.2M | |
| Operating Income | (13.6M) | (20.6M) | (45.5M) | (50.3M) | (29.8M) | (31.3M) | |
| Net Income From Continuing Ops | (13.7M) | (20.6M) | (31.6M) | (30.9M) | (28.0M) | (29.4M) | |
| Ebit | (13.6M) | (20.6M) | (45.5M) | (50.3M) | (29.8M) | (31.3M) | |
| Research Development | 3.5M | 10.5M | 10.9M | 19.0M | 14.2M | 9.4M | |
| Ebitda | (13.4M) | (20.4M) | (45.3M) | (50.1M) | (29.5M) | (31.0M) | |
| Cost Of Revenue | 91.5K | 150.6K | 229.5K | 219.9K | 248.4K | 182.1K | |
| Total Operating Expenses | 14.1M | 20.7M | 38.7M | 41.3M | 29.5M | 24.1M | |
| Reconciled Depreciation | 150.6K | 229.5K | 220.4K | 219.9K | 239.6K | 189.3K | |
| Income Before Tax | (13.7M) | (20.6M) | (31.6M) | (30.9M) | (28.1M) | (29.5M) | |
| Total Other Income Expense Net | (100.5K) | (34.5K) | 13.8M | 19.4M | 1.7M | 1.6M | |
| Net Income Applicable To Common Shares | (13.7M) | (20.6M) | (31.6M) | (30.9M) | (27.8M) | (29.2M) | |
| Net Income | (14.0M) | (20.6M) | (24.7M) | (11.5M) | (28.1M) | (26.7M) | |
| Income Tax Expense | 299.4K | 7.4K | (6.9M) | (19.4M) | 5.0 | 5.25 |
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cardiol Stock
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.